Ellen de Brabander - 01 Mar 2023 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
Executive Vice President of Innovation and Regulatory Affairs
Signature
/s/ Catherine S. Powell, as Attorney-in-Fact for Ellen de Brabander
Issuer symbol
ELAN
Transactions as of
01 Mar 2023
Net transactions value
-$26,664
Form type
4
Filing time
03 Mar 2023, 19:59:55 UTC
Previous filing
03 Nov 2022
Next filing
05 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELAN Common Stock Tax liability $26,664 -2,368 -4.8% $11.26 46,468 01 Mar 2023 Direct F1
transaction ELAN Common Stock Award $0 +45,338 +98% $0.000000 91,806 01 Mar 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Employee Stock Option (right to buy) Award $0 +103,550 $0.000000 103,550 01 Mar 2023 Common Stock 103,550 $11.26 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan.
F2 Grant of restricted stock units pursuant to the Amended and Restated 2018 Elanco Stock Plan on March 1, 2023, one-third vesting on March 1, 2024, one-third vesting on March 1, 2025, and the remaining vesting on March 1, 2026.
F3 Grant of stock options vesting as follows: one-third vesting on March 1, 2024, one-third vesting on March 1, 2025, and the remaining vesting on March 1, 2026.

Remarks:

Executive Vice President of Innovation and Regulatory Affairs